innocrinpharma.com
Our Programs | Innocrin
http://innocrinpharma.com/product-development/our-programs
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. Castration-Resistant Prostate Cancer (CRPC). Abiraterone or enzalutamide are also difficult to sequence due to high cross-resistance mechanisms that are fully understood. That is, once a man’s cancer becomes resistant to either abiraterone or enzalutamide, there is a low probability that the 2. Drug will be effective. Many of the resistance mechanisms that make abiraterone and en...
innocrinpharma.com
Investors | Innocrin
http://innocrinpharma.com/investors
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. Fred Eshelman is a founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies. Dr. Eshelman typically serves on the board of portfolio companies. Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests. Established ...
innocrinpharma.com
Products | Innocrin
http://innocrinpharma.com/product-development
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients with Castration-Resistant Prostate Cancer. A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients with Metastatic Castration Resistant Prostrate Cancer Who Have Previously Been Treated With Enzalutamide.
innocrinpharma.com
Board of Directors | Innocrin
http://innocrinpharma.com/about-us/board-of-directors
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. Douglas Reed, M.D. General Partner, Hatteras Venture Partners, Chairman. Andrew von Eschenbach, M.D. Fred Eshelman, PharmD. Previously, he found and served as CEO and Executive Chairman of Pharmaceutical Product Development, Inc. (PPDI, NASDAQ) until sale of the company to private equity interests (Carlyle, Hellman and Friedman). His career has also included positions as Seni...He is...
innocrinpharma.com
Clinical Trials | Innocrin
http://innocrinpharma.com/product-development/clinical-trials
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients with Castration-Resistant Prostate Cancer. A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients with Metastatic Castration Resistant Prostrate Cancer Who Have Previously Been Treated With Enzalutamide.
innocrinpharma.com
Our Pipeline | Innocrin
http://innocrinpharma.com/our-pipeline
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. Generation leads into clinical development.
innocrinpharma.com
Conferences | Innocrin
http://innocrinpharma.com/investors/conferences
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. PCF’s 23rd Annual Scientific Retreat. October 27-29, 2016. William Moore, CEO. Biocentury Biotech Industry Newsmakers Conference. September 9-10, 2016. New York, NY. William Moore, CEO. Canaccord Genuity Growth Conference. August 10-11, 2016. William Moore, CEO. American Society of Clinical Oncology (ASCO). June 3-7, 2016. Pdf: view poster here. March 1-2, 2016. William Moore, CEO.
innocrinpharma.com
Partnering | Innocrin
http://innocrinpharma.com/partnering
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. We value and wish to hear from creative partners who share our motivation to accelerate seviteronel development for the treatment of castration-resistant prostate cancer and breast cancer. We also have interest to hear from parties who would like more information on our broad CYP17 lyase inhibitor pipeline for the treatment of oncology and non-oncology indications.
innocrinpharma.com
About Us | Innocrin
http://innocrinpharma.com/about-us
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. CYP17 lyase inhibitors have high commercial potential for the treatment of CRPC and breast cancer as well as other cancers that utilize androgens as growth factors (e.g., ovarian, bladder, hepatocellular, and lung). Selective CYP17 lyase inhibitors also have potential for the treatment of non-oncologic syndromes that are due to the condition of androgen excess.
innocrinpharma.com
Management | Innocrin
http://innocrinpharma.com/about-us/management
We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer. William R. Moore, Ph.D. President, CEO and Director. William Moore, Ph.D. Joel Eisner, Ph.D. Vice President, Clinical Operations. Ronald A. Fleming, Pharm.D. Vice President, Translational Research. Michael Kurman, MD. Charles F. Osborne, Jr. CPA. Chief Financial Officer and Corporate Secretary. Aaron (Ron) Weitzman, MD. Sr Medical Prostate Cancer Adviser.
